Valuation: Assembly Biosciences, Inc.

Market Cap 488M 429M 404M 369M 690M 46.83B 696M 4.84B 1.88B 23.85B 1.83B 1.79B 77.5B P/E 2026 *
-203x
P/E 2027 * -8.67x
Enterprise Value 402M 353M 333M 304M 568M 38.53B 573M 3.98B 1.54B 19.63B 1.51B 1.47B 63.77B EV / Sales 2026 *
6.33x
EV / Sales 2027 * 10.6x
Free-Float
72.34%
Yield 2026 *
-
Yield 2027 * -
1 day-1.29%
1 week-7.14%
Current month-29.65%
1 month-31.18%
3 months-11.72%
6 months-17.21%
Current year-30.43%
1 week 23.15
Extreme 23.15
25.89
1 month 23.15
Extreme 23.15
37.01
Current year 21.8
Extreme 21.795
37.01
1 year 21.8
Extreme 21.795
39.7
3 years 7.69
Extreme 7.692003
39.7
5 years 7.69
Extreme 7.692003
42.6
10 years 7.69
Extreme 7.692003
808.32
Manager TitleAgeSince
Chief Executive Officer 50 31/12/2022
Director of Finance/CFO - 04/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 03/06/2026
Director/Board Member 61 13/12/2017
Director/Board Member 68 05/08/2019
Date Insider Type Main position Quantity % Market Cap. Importance
04/06/26 Free

Director

8,000 0.0514%
04/06/26 Free

Director

8,000 0.0514%
04/06/26 Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-1.29%-7.14%-8.96%+113.29% 488M
+1.46%+5.87%+5.75%+33.71% 47.56B
+2.67%+2.31%+47.50%+38.37% 44.09B
-1.38%+3.42%+9.39%+88.88% 41.5B
+4.78%+2.01%+352.12%+566.20% 40.88B
-0.62%+0.11%+1.12%+46.02% 29.67B
+0.56%+0.67%+25.08%+155.71% 17.23B
+2.05%+4.04%+24.47%+41.67% 15.06B
+3.39%-6.86% - - 14.65B
+7.38%+17.54%-2.25% - 13.82B
Average +0.77%+0.03%+50.47%+135.48% 26.5B
Weighted average by Cap. +0.94%+0.95%+71.72%+147.42%

Financials

2026 *2027 *
Net sales 63.43M 55.75M 52.52M 48M 89.69M 6.09B 90.46M 629M 244M 3.1B 238M 233M 10.07B 34.12M 29.99M 28.25M 25.82M 48.25M 3.27B 48.66M 338M 131M 1.67B 128M 125M 5.42B
Net income 1.4M 1.23M 1.16M 1.06M 1.98M 135M 2M 13.91M 5.4M 68.58M 5.27M 5.15M 223M -56.83M -49.95M -47.06M -43M -80.37M -5.45B -81.05M -563M -219M -2.78B -213M -209M -9.03B
Net Debt -86.48M -76.01M -71.61M -65.44M -122M -8.3B -123M -857M -333M -4.23B -325M -318M -13.73B -127M -112M -105M -96.01M -179M -12.17B -181M -1.26B -488M -6.2B -476M -466M -20.15B
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
24/09/26 US$23.66 -1.29% 179,004
23/09/26 US$23.97 -5.82% 275,247
22/09/26 US$25.45 +0.04% 1,070,124
21/09/26 US$25.44 +1.88% 211,868
18/09/26 US$24.97 -1.46% 1,413,893
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
23.97USD
Average target price
52.00USD
Spread / Average Target
+116.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock